cagrilintide semaglutide phase 2 weight loss Updates in Medicine | 🔬 REDEFINE 2: CagriSema in T2D + Obesity Original article link in bio 👥 3a RCT in 1206 adults with T2D (BMI ≥27, HbA1c 7–10%) 💉 CagriSema: a novel dual-pathway approach

CagriSema: a novel dual pathway approach to target obesity and its complications In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit

SKU: 33665880468 · From iglepidom.org